Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SI-B001 + docetaxel
- Development stage
- Phase 3
- Lead developer
- Baili Biopharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SI-B001 + docetaxel is a combination therapy consisting of SI-B001 (izalontamab), a first-in-class EGFR×HER3 bispecific antibody, and docetaxel, a taxane chemotherapy agent. SI-B001 works by simultaneously binding to both EGFR and HER3 receptors on cancer cells, blocking their phosphorylation and activation, thus preventing downstream signaling that leads to cancer cell proliferation. Docetaxel works by disrupting the microtubule network essential for cell division. This combination is being investigated primarily for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) in patients who have failed prior therapies.
- Other names
- izalontamab + docetaxel
02
Targets
EGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SI-B001 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SI-B001 + docetaxel.